Wednesday, July 8, 2026

Drug profile · INN

carprofen

carprofen (RIMADYL) is a cyclooxygenase-2 inhibitor. Route of administration: oral. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — carprofen
US status
approved
Class
Route
ORAL
Patents
0
Programs
0
Data quality
0.84

Quick answer

carprofen (RIMADYL) is a cyclooxygenase-2 inhibitor. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN carprofen
Brand RIMADYL
Mechanism Cyclooxygenase-2 inhibitor
Target Prostaglandin G/H synthase 2
Route ORAL
Formulation TABLET

Mechanism of action

Cyclooxygenase-2 inhibitor

Primary target: Prostaglandin G/H synthase 2

Approval history

Authority Status Date
FDA approved

Related & competitor drugs

  1. celecoxib Antineoplastic and immunomodulating agents (L01)
  2. etodolac Cyclooxygenase-2 inhibitor
  3. meloxicam Cyclooxygenase-2 inhibitor
  4. nabumetone Cyclooxygenase-2 inhibitor
  5. rofecoxib Cyclooxygenase-2 inhibitor
  6. valdecoxib Musculo-skeletal system (M01)

Frequently asked questions

What is carprofen?

carprofen (RIMADYL) is a cyclooxygenase-2 inhibitor. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for carprofen?

RIMADYL is a marketed brand name for carprofen. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of carprofen?

carprofen has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.